Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in <i>NPM1</i>-mutant AMLJan Philipp Bewersdorf, Maximilian Stahl, Evan C. Chen et al.|Blood Advances|2024Cited by 12
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in <i>IDH1</i>‐ or <i>IDH2</i>‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort studyJan Philipp Bewersdorf, Maximilian Stahl, Shai Shimony et al.|American Journal of Hematology|2024Cited by 9
Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid LeukemiaAlexandre Iat, Sylvain Garciaz, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 2
Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk CytogeneticsLuis E. Aguirre, Maximilian Stahl, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 1
The Prognostic and Predictive Value of <i>RUNX1</i> Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort StudyRebecca P. Bystrom, Maximilian Stahl, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 0